Merck & Co.

Red arrow decreasing

Biotech

Neuphoria nixes social anxiety program after phase 3 flop

Neuphoria’s stock has plummeted 67% after the announcement, dropping from Monday’s close of $15.40 per share to $5 as of 10 a.m. ET today.

Gabrielle Masson Oct 21, 2025 10:44am

Blue race track

Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Oct 20, 2025 4:00pm

An arrow incrementally going up stairs before pointing straight up Blue background

ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test

Oct 20, 2025 10:45am

vials vaccine research vaccines factory manufacturing

Evaxion stock slips on phase 2 cancer vax data

Oct 17, 2025 2:07pm

cardboard box with office belongings and a desk chair

Big pharma cuts and gene therapy woes: Inside Q3's layoffs

Oct 3, 2025 4:30pm

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Sep 25, 2025 7:00am